Innova Captab Limited reported strong financial results for FY 2025-26, with revenue rising 31.1% to ₹1,630.02 crore. Growth was powered by its CDMO and Branded Generics divisions, alongside the successful scale-up of its Kathua manufacturing facility. The company announced a ₹2 per share interim dividend and addressed minor financial statement reclassifications that do not impact overall profitability.
Innova Captab FY26 Revenue Climbs 31% to ₹1,630 Crore
Revenue reached ₹1,630.02 crore, while Profit After Tax (PAT) grew by 12.5% to ₹143.18 crore.
Reader Takeaway: Strong revenue growth from CDMO and generics is tempered by minor technical financial reclassifications in the annual report.
What just happened
Innova Captab released its Integrated Annual Report for FY26, showcasing double-digit growth across its core business segments. The CDMO business grew 23.8% to ₹1,133.35 crore, aided by the maturation of the Kathua facility. Meanwhile, the Branded Generics segment saw a sharp 51.4% increase, reaching ₹496.67 crore. The board has declared an interim dividend of ₹2 per share (face value ₹10).
Why this matters
The results highlight the company's ability to scale operations efficiently. The transition of the Kathua plant from commercialization to stable scale-up is a key milestone that supports future margin expansion. The dividend announcement signals management’s confidence in sustained cash flows despite the reported technical revisions.
The Corrigendum
The company issued a corrigendum regarding its standalone and consolidated financial statements. Adjustments were made to deferred tax assets and the classification of supplier finance arrangements. Management confirmed these changes do not affect the total assets, liabilities, or net profit of the group.
What to track next
Investors should monitor the company's operating leverage at the Kathua site and the progress of its branded generics expansion, which is currently the fastest-growing part of the portfolio.